Efficacy and safety of basiliximab in kidney transplantation.
The efficacy and safety of basiliximab, in combination with different maintenance regimens, are extensively addressed in the available literature. Basiliximab reduces the incidence of acute rejection, allows a safe reduction of steroid dosage, and is associated with economic savings, although there is substantially no proof that basiliximab prolongs either patient or graft survival. Initial basiliximab administration entails a low-risk and is associated with fewer adverse events than T cell depleting agents. However, life-threatening reactions were reported following re-exposure to basiliximab in recipients who lost graft function early after transplantation and, therefore, discontinued all immunosuppressive agents.
Boggi
Ugo
U
Division of Surgery in Uremic and Diabetic Patients (General and Transplant Surgery), Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, Pisa, Italy. uboggi@med.unipi.it
Vistoli
Fabio
F
Signori
Stefano
S
Del Chiaro
Marco
M
Amorese
Gabriella
G
Barsotti
Massimiliano
M
Rizzo
Gaetano
G
Marchetti
Piero
P
Danesi
Romano
R
Del Tacca
Mario
M
Mosca
Franco
F
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000077552:Basiliximab; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D017850:Economics, Pharmaceutical; D006084:Graft Rejection / Q000517:prevention & control; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016030:Kidney Transplantation; D011993:Recombinant Fusion Proteins / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012307:Risk Factors; D013601:T-Lymphocytes
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab